Induction of apoptosis in murine ACTH‐secreting pituitary adenoma cells by bromocriptine
Open Access
- 14 February 1994
- journal article
- Published by Wiley in FEBS Letters
- Vol. 339 (1-2) , 73-75
- https://doi.org/10.1016/0014-5793(94)80387-0
Abstract
Bromocriptine, a dopamine agonist, is now an accepted primary therapeutic agent for patients with prolactinomas and other pituitary adenomas. In this study, we demonstrated that bromocriptine inhibited the proliferation of murine ACTH‐secreting pituitary adenoma (AtT‐20) cells. In addition, the antitumor activity of bromocriptine was inhibited both by actinomycin D and cycloheximide, suggesting that it was dependent on new RNA and protein synthesis. Interestingly, the results of DNA fragmentation assays and cell cycle analysis clearly demonstrated that bromocriptine induced apoptosis in AtT‐20 cells.Keywords
This publication has 25 references indexed in Scilit:
- DNA Damage and Cell Killing by Camptothecin and Its Derivative in Human Leukemia HL‐60 CellsJapanese Journal of Cancer Research, 1993
- Cell Death Mechanisms and the Immune SystemImmunological Reviews, 1991
- Developmental cell death: morphological diversity and multiple mechanismsBrain Structure and Function, 1990
- Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosisNature, 1990
- DNA fragmentation in cytolysisImmunology Today, 1989
- Cytocidal Effect of Bromocriptine on Human Pituitary Adenoma CellsNeurologia medico-chirurgica, 1985
- The Mechanism of the Suppressive Action of Bromocriptine on Adrenocorticotropin Secretion in Patients with Cushing′s Disease and Nelson′s Syndrome*Journal of Clinical Endocrinology & Metabolism, 1980
- BROMOCRIPTINE IN PITUITARY TUMOURSThe Lancet, 1978
- Changes in Plasma Growth Hormone Levels in Normal and Acromegalic Subjects Following Administration of 2-Bromo-?-ErgocryptineJournal of Clinical Endocrinology & Metabolism, 1975
- Galactorrhoea: Successful Treatment with Reduction of Plasma Prolactin Levels by Brom-ergocryptineBMJ, 1972